全文获取类型
收费全文 | 696篇 |
免费 | 42篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 38篇 |
妇产科学 | 2篇 |
基础医学 | 63篇 |
口腔科学 | 40篇 |
临床医学 | 46篇 |
内科学 | 193篇 |
皮肤病学 | 13篇 |
神经病学 | 12篇 |
特种医学 | 81篇 |
外科学 | 79篇 |
综合类 | 62篇 |
预防医学 | 27篇 |
眼科学 | 8篇 |
药学 | 21篇 |
肿瘤学 | 38篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 10篇 |
2020年 | 8篇 |
2019年 | 11篇 |
2018年 | 10篇 |
2017年 | 4篇 |
2016年 | 11篇 |
2015年 | 19篇 |
2014年 | 24篇 |
2013年 | 21篇 |
2012年 | 16篇 |
2011年 | 15篇 |
2010年 | 34篇 |
2009年 | 39篇 |
2008年 | 18篇 |
2007年 | 34篇 |
2006年 | 38篇 |
2005年 | 17篇 |
2004年 | 14篇 |
2003年 | 10篇 |
2002年 | 12篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 17篇 |
1998年 | 42篇 |
1997年 | 32篇 |
1996年 | 40篇 |
1995年 | 18篇 |
1994年 | 19篇 |
1993年 | 22篇 |
1992年 | 4篇 |
1991年 | 9篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 24篇 |
1987年 | 11篇 |
1986年 | 11篇 |
1985年 | 19篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1966年 | 3篇 |
排序方式: 共有745条查询结果,搜索用时 15 毫秒
81.
Fifteen allograft transplant recipients acquired lymphoproliferative disorders after immunosuppressive therapy with cyclosporine and steroids. Many of these lymphoproliferative disorders regressed or disappeared completely after reduction of cyclosporine dose. This disease has several aspects that distinguish it from usual posttransplantation lymphomas that occur with regimens that do not contain cyclosporine. The time course from transplantation to onset of lymphoma is relatively short, with an average of approximately 8 months. Organs show a wide spectrum of abnormalities typical of other immunosuppression-associated lymphomas, but there is unique sparing of the central nervous system. The tumor is also unique in that it responds to a decrease in the cyclosporine dose. 相似文献
82.
Birringer M Kuhlow D Pfluger PT Landes N Schulz TJ Glaubitz M Florian S Pfeiffer A Schuelke M Brigelius-Flohé R Ristow M 《European journal of nutrition》2007,46(7):397-405
Background Conflicting evidence suggests a possible role for vitamin E in mammalian glucose metabolism and the protection from type 2
diabetes. The alpha-tocopherol transfer protein (α-TTP) mediates the transfer of α-tocopherol (α-TOH) from hepatocytes to
very-low-density lipoproteins, thereby controlling plasma levels of α-TOH.
Aim of the study The aim of this study was to investigate the putative impact of α-TTP knock-out on glucose metabolism in mice.
Methods Mice deficient for α-TTP and wild-type control littermates were fed a diet containing 200 mg α-tocopheryl acetate per kg to
ameliorate α-TOH deficiency in knock-out mice. We investigated fasting and postprandial plasma glucose, insulin and triglyceride
levels of both groups of mice at different ages. All genotypes and age groups were further subjected to glucose and insulin
tolerance tests, and number of insulin-producing islets of Langerhans were determined.
Results Plasma α-TOH levels of knock-out mice were 34% the levels of wild-type controls: Any signs of α-TOH deficiency were absent
at any age. Unexpectedly, serum glucose levels both in the fasted and in the fed state were lower in α-TTP-deficient mice
at any age. Removal rates for intraperitoneally injected glucose were found to be significantly increased in young α-TTP-deficient
mice. This improved glucose tolerance was caused by increased insulin secretion in response to an intraperitoneal glucose
challenge due to an increased number of pancreatic islets, as well as by increased sensitivity to intraperitoneally injected
insulin, both significantly promoting glucose metabolism in α-TTP-deficient mice.
Conclusions Our findings suggest that α-TTP-deficiency in states of α-TOH supplementation unexpectedly promotes glucose tolerance in mice
due to both increased insulin secretion and insulin action, suggesting differential roles of α-TTP and α-TOH in the pathogenesis
of type 2 diabetes mellitus.
Marc Birringer and Doreen Kuhlow have contributed equally to this publication. 相似文献
83.
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones 总被引:5,自引:0,他引:5 下载免费PDF全文
Norris AW Chen L Fisher SJ Szanto I Ristow M Jozsi AC Hirshman MF Rosen ED Goodyear LJ Gonzalez FJ Spiegelman BM Kahn CR 《The Journal of clinical investigation》2003,112(4):608-618
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by thiazolidinediones (TZDs) improves insulin resistance by increasing insulin-stimulated glucose disposal in skeletal muscle. It remains debatable whether the effect of TZDs on muscle is direct or indirect via adipose tissue. We therefore generated mice with muscle-specific PPARgamma knockout (MuPPARgammaKO) using Cre/loxP recombination. Interestingly, MuPPARgammaKO mice developed excess adiposity despite reduced dietary intake. Although insulin-stimulated glucose uptake in muscle was not impaired, MuPPARgammaKO mice had whole-body insulin resistance with a 36% reduction (P < 0.05) in the glucose infusion rate required to maintain euglycemia during hyperinsulinemic clamp, primarily due to dramatic impairment in hepatic insulin action. When placed on a high-fat diet, MuPPARgammaKO mice developed hyperinsulinemia and impaired glucose homeostasis identical to controls. Simultaneous treatment with TZD ameliorated these high fat-induced defects in MuPPARgammaKO mice to a degree identical to controls. There was also altered expression of several lipid metabolism genes in the muscle of MuPPARgammaKO mice. Thus, muscle PPARgamma is not required for the antidiabetic effects of TZDs, but has a hitherto unsuspected role for maintenance of normal adiposity, whole-body insulin sensitivity, and hepatic insulin action. The tissue crosstalk mediating these effects is perhaps due to altered lipid metabolism in muscle. 相似文献
84.
Walter Luyten Peter Antal Bart P. Braeckman Jake Bundy Francesca Cirulli Christopher Fang-Yen Georg Fuellen Armand Leroi Qingfei Liu Patricia Martorell Andres Metspalu Markus Perola Michael Ristow Nadine Saul Liliane Schoofs Karsten Siems Liesbet Temmerman Tina Smets Alicja Wolk Suresh I. S. Rattan 《Biogerontology》2016,17(4):771-782
Human longevity continues to increase world-wide, often accompanied by decreasing birth rates. As a larger fraction of the population thus gets older, the number of people suffering from disease or disability increases dramatically, presenting a major societal challenge. Healthy ageing has therefore been selected by EU policy makers as an important priority (http://www.healthyageing.eu/european-policies-and-initiatives); it benefits not only the elderly but also their direct environment and broader society, as well as the economy. The theme of healthy ageing figures prominently in the Horizon 2020 programme (https://ec.europa.eu/programmes/horizon2020/en/h2020-section/health-demographic-change-and-wellbeing), which has launched several research and innovation actions (RIA), like “Understanding health, ageing and disease: determinants, risk factors and pathways” in the work programme on “Personalising healthcare” (https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/693-phc-01-2014.html). Here we present our research proposal entitled “ageing with elegans” (AwE) (http://www.h2020awe.eu/), funded by this RIA, which aims for better understanding of the factors causing health and disease in ageing, and to develop evidence-based prevention, diagnostic, therapeutic and other strategies. The aim of this article, authored by the principal investigators of the 17 collaborating teams, is to describe briefly the rationale, aims, strategies and work packages of AwE for the purposes of sharing our ideas and plans with the biogerontological community in order to invite scientific feedback, suggestions, and criticism. 相似文献
85.
Storb R; Prentice RL; Banaji M; Witherspoon RP; Sullivan KM; Stewart P; Sanders JE; Mason M; Doney K; Deeg J; Clift RA; Buckner CD; Appelbaum FR; Thomas ED 《Blood》1983,61(4):672-675
The present study in patients with aplastic anemia was undertaken to determine whether exposure of recipients to donor blood products 24 hr before preparation with cyclophosphamide (1) enhanced the rate of sustained engraftment of marrow from HLA-identical siblings as suggested by animal experiments, (2) increased the rejection rate, in particular in transfused patients who may already have been exposed to donor antigens by blood products, or (3) was of no relevance to the outcome of transplantation of marrow from HLA-identical siblings. One- hundred fifty-five patients were studied, of whom 78 received blood products from the marrow donor 24 hr before cyclophosphamide and 77 did not. A binary logistic regression analysis was applied to the data, simultaneously considering five previously known risk factors for rejection. Results showed that preceding transfusion of donor blood products had neither a significant beneficial nor detrimental effect on the incidence of sustained engraftment. 相似文献
86.
世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染 总被引:16,自引:1,他引:16
Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 《胃肠病学》2007,12(1):40-52
我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 相似文献
87.
88.
George G Zhanel Godfrey KM Harding Stuart Rosser Daryl J Hoban James A Karlowsky Michelle Alfa Amin Kabani John Embil Alfred Gin Trevor Williams Lindsay E Nicolle 《The Canadian Journal of Infectious Diseases & Medical Microbiology》2000,11(1):38-41
OBJECTIVE:
To determine the prevalence of vancomycin-resistant enterococci (VRE) bowel colonization in hospitalized patients in Manitoba who had stool specimens collected for Clostridium difficile toxin and/or culture testing.DESIGN:
Two tertiary care and five community hospitals in Winnipeg and three rural Manitoba community hospitals participated in this study. From January 1 to December 31, 1997 stool specimens, one per patient, submitted to hospital microbiology laboratories for C difficile toxin and/or culture testing were screened for VRE on colistin-nalidixic acid-vancomycin (6 μg/mL) (CNAV) agar plates. The study was divided into six, eight-week intervals. Stool specimens received in the first two weeks of each eight week interval were screened for VRE.MAIN RESULTS:
A total of 1408 stool specimens were submitted over the 48-week study period. Sixty-seven (4.8%) patients with VRE colonization of their lower gastrointestinal tract were identified. Three of the 67 (4.5%) VRE isolates were Enterococcus faecium, with the remaining 64 (95.5%) were Enterococcus gallinarum. The three vancomycin-resistant E faecium -VREF- (from two different Winnipeg hospitals) demonstrated the vanA genotype, and were resistant to vancomycin, teicoplanin and ampicillin. All three VREF isolates also demonstrated high level resistance to both gentamicin and streptomycin but were susceptible to quinuprisitin/dalfopristin and . LY333328CONCLUSION:
VRE colonization in hospitalized patients in Manitoba is infrequent and most commonly due to E gallinarum. The prevalence of VREF colonization in the patients studied was 0.2% (three of 1408).Key Words: Manitoba, Prevalence, Vancomycin-resistant enterococciVancomycin-resistant Enterococcus faecium (VREF) accounts for up to 65% of E faecium isolates in hospitalized patients across the United States and is endemic in many North American tertiary care institutions (1,2). The management of these infections presents a significant clinical challenge because species of the genus Enterococcus, and in particular E faecium, are frequently resistant to several antimicrobial agents (3). High level penicillin resistance, high level aminoglycoside resistance and most recently vancomycin resistance are emerging as significant concerns in the treatment of enterococcal infections. This has prompted the development and evaluation of new antimicrobial agents such as quinupristin/dalfopristin and , a glycopeptide, which may offer activity against enterococci resistant to conventional therapy ( LY3333282).VREF is not endemic in Manitoba hospitals, and infection with VREF is extremely rare (4). However, the prevalence of VREF lower gastrointestinal tract (GIT) carriage, which frequently precedes infection (5,6), is presently unknown for patients hospitalized in Manitoba. To determine whether the lack of VREF endemnicity correlated with an absence of lower GIT colonization, we assessed lower GIT carriage of VREF for patients hospitalized in 10 Manitoba hospitals from January 1 to December 31, 1997. Our study was consistent with Centers for Disease Control and Prevention guidelines (Atlanta, Georgia) that suggest surveillance programs for vancomycin-resistant enterococci (VRE) be undertaken on an intermittent basis in areas where VRE is not known to be endemic (6). Isolates of VREF identified were phenotypically and genotypically characterized, and tested for their susceptibilities against a panel of antimicrobial agents. 相似文献89.
90.
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors 总被引:3,自引:3,他引:3
Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey TR; Clift RA; Doney K; Flowers M; Hansen JA; Martin PJ; Matthews DC; Sanders JE; Shulman H; Sullivan KM; Witherspoon RP; Storb R 《Blood》1996,87(1):51-58
From 1990 to 1993 we performed a prospective study of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) in 30 patients with refractory anemia (RA) undergoing related (n = 17) or unrelated (n = 13) donor marrow transplantation. Nineteen patients survive disease free (63% 3- year actuarial disease-free survival [DFS]) and no patient relapsed. These results were compared to those of 38 historical controls with RA treated with cyclophosphamide and total body irradiation, of whom 22 are disease-free survivors and 1 relapsed. After correcting for significant variables between the two treatment groups, we found no statistically significant difference in outcome based on preparative regimen. Combining data from these 68 patients plus 2 additional patients with RA treated before 1993 with busulfan and cyclophosphamide, we identified four variables independently associated with improved survival: younger age, shorter disease duration, lower neutrophil count pretransplant, and lower hematocrit pretransplant. We also found that 15 patients 40 to 55 years of age had a 46% 3-year actuarial DFS and 26 patients receiving unrelated or mismatched related donor marrow had a 50% 3-year actuarial DFS. We conclude that there does not appear to be any significant difference in outcome based on preparative regimen in this patient population. In addition, allogeneic bone marrow transplantation may be a reasonable approach to therapy of RA early after diagnosis. However, whether early intervention with transplantation prolongs survival over that expected without transplantation cannot be ascertained with certainty from available data. 相似文献